Project: Novel RNA based therapies for treatment-resistant forms of severe cardiomyopathy caused by LMNA mutations

Acronym	Variation (Reference Number: 10. JTC-2016_156)
Duration	01/05/2017 - 30/04/2020
Project Topic	Some forms of heart failure are often very difficult to treat. Patients who have a mutation in Lamin A/C can develop a form of heart disease that often does not respond well enough to existing therapies. VARIATION aims to develop a new technology to inhibit mutated Lamin A to halt the disease. The project will test this new RNA based technology in human cell that are derived from stem cells obtained from patients that actually carry the disease. VARIATION is expected to provide the first steps towards a treatment that is applicable to most patients that carry such a mutation and can halt progression of the associated heart failure.
Network	ERA-CVD
Call	ERA-CVD Joint Transnational Call 2016

Number	Name	Role	Country
1	University of Amsterdam	Coordinator	Netherlands
2	Charité – University Hospital Berlin, Campus Virchow (CVK)	Partner	Germany
3	Technion Israel Institute of technology	Partner	Israel
4	Hospital Pitié-Salpêtrière	Partner	France